Drotrecogin alfa (activated): A pharmacoeconomic review of its use in severe sepsis

PharmacoEconomics

Volumn 22, Issue 7, 2004, Pages 445-476

  Frampton, James E ^a   Foster, Rachel H ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN;

BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; EPIDEMIOLOGICAL DATA; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE PLANNING; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HOSPITAL COST; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LIFE EXPECTANCY; MONTE CARLO METHOD; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; NORTH AMERICA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEPSIS; SEPTIC SHOCK; SURVIVAL; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED STATES; WESTERN EUROPE;

ANTI-INFECTIVE AGENTS; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; EUROPE; HEALTH CARE COSTS; HUMANS; NORTH AMERICA; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS; TREATMENT OUTCOME;

EID: 2942550860     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422070-00004     Document Type: Review

References (103)

1. Levi M, De Jonge E, Van der Poll T. Recombinant human activated protein C (XIGRIS®). Int J Clin Pract 2002 Sep; 56 (7): 542-5
2. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992 Jun; 101 (6): 1644-55
3. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003 Apr; 31 (4): 1250-6
4. Leady M, Kraft M, Alaniz C. Recombinant human activated protein c (rhapc) or drotrecogin alfa (activated). PT 2002; 27 (4): 190-4
5. Patel GP, Gurka DP, Balk RA. New treatment strategies for severe sepsis and septic shock. Curr Opin Crit Care 2003 Oct; 9 (5): 390-6
6. Bernard GR. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Crit Care Med 2003 Jan; 31 (1 Suppl.): S85-93
7. McCoy C, Matthews SJ. Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis. Clin Ther 2003 Feb; 25 (2): 396-421
8. Bearden DT, Garvin CG. Recombinant human activated protein C for use in severe sepsis. Ann Pharmacother 2002 Sep; 36 (9): 1424-9
9. Pastores SM. Drotrecogin alfa (activated): A novel therapeutic strategy for severe sepsis. Postgrad Med J 2003; 79 (927): 5-10
10. Maglio D. Drotrecogin alfa (activated) for severe sepsis. Conn Med 2002 Mar; 66 (3): 145-50
11. Kanji S, Devlin JW, Piekos KA, et al. Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis. Pharmacotherapy 2001 Nov; 21 (11): 1389-402
12. Lyseng-Williamson KA, Perry C. Drotrecogin alfa (activated). Drugs 2002; 62 (4): 617-30
13. Rudis MI, Fish DN. Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated). Pharmacotherapy 2002 Dec; 22 (12 Pt 2): 182S-95S
14. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001 Mar 8; 344 (10): 699-709
15. Baumgartner JD, Calandra T. Treatment of sepsis: past and future avenues. Drugs 1999 Feb; 57 (2): 127-32
16. Krishnagolpalan R, Dellinger RP. Innovative therapies for sepsis. Biodrugs 2001; 15 (10): 645-54
17. Abraham E, Laterre PF, Garbino J, et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001 Mar; 29 (3): 503-10
18. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001 Nov 8; 345 (19): 1368-77
19. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002 Aug 21; 288 (7): 862-71
20. Opal SM. Clinical trial design and outcomes in patients with severe sepsis. Shock 2003 Oct; 20 (4): 295-302
21. Wood KA, Angus DC. Pharmacoeconomic implications of new therapies in sepsis. Pharmacoeconomics. In press
22. O'Brien JM, Abraham E. New approaches to the treatment of sepsis. Clin Chest Med 2003; 24: 521-48
23. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome and associated costs of care. Crit Care Med 2001 Jul; 29 (7): 1303-10
24. Dasta JF, Cooper LM. Impact of drotrecogin alfa (activated) on resource use and implications for reimbursement. Pharmacotherapy 2002 Dec; 22 (12 Pt 2): 216S-22S
25. Wenzel RP, Edmond MG. Severe sepsis - national estimates. Crit Care Med 2001 Jul; 29 (7): 1472-3
26. Braun L, Cooper LM. Hospital and follow-up costs in a severe sepsis managed care population. Crit Care Med 2002 Dec; 30 (12 Suppl.): 127
27. Vanscoy GJ. Management challenge with drotrecogin alfa (activated). Am J Health Syst Pharm 2002 Feb 15; 59 Suppl. 1: S23-9
28. Meyer KL, Faris R, Rowden A. The cost of severe sepsis at a tertiary care teaching institution [abstract no. PIN 44]. Value Health. 2003 May; 6: 268
29. Weycker D, Akhras KS, Edelsberg J, et al. Long-term mortality and medical-care charges in patients with severe sepsis. Crit Care Med 2003 Sep; 31 (9): 2316-23
30. Greener M. First economic analysis paints shocking picture of severe sepsis in Europe. Pharmacoecon Outcomes News 2001 Dec 15; 343 (34)
31. Hughes M, Wallace PGM. New therapies for sepsis. Cpd Anaesthesia 2002; 4 (3): 130-5
32. National statistics. Census 2001. England and Wales [online]. Available from URL: http://www.statistics.gov.uk/census2001/pyramids/pages/727.asp [Accessed 2003 Dec 8]
33. Schmid A, Pugin J, Schneider H, et al. Cost of illness imposed by severe sepsis in Switzerland [abstract no. 352]. Intensive Care Med 2003; 29 (Suppl. 1): S94
34. Swiss Federal Statistical Office. Demographic changes in absolute figures Switzerland [online]. Available from URL: http://www.statistik.admin.ch/ stat_ch/ber00/vz/cc/evz-cc01-01.htm [Accessed 2003 Nov 27]
35. Burchardi H, Schneider H. Severe sepsis: ICU costs, cost of illness and cost-effectiveness of therapy. Pharmacoeconomics. In press
36. MacKirdy F, Harris G, Mackenzie SJ. The epidemiology of sepsis in Scottish intensive care units [abstract no. P27]. Crit Care 2003; 7 (Suppl. 2): S14
37. Edbrooke DL, Hibbert CL, Kingsley JM, et al. The patient-related costs of care for sepsis patients in a United Kingdom adult general intensive care unit. Crit Care Med 1999 Sep; 27 (9): 1760-7
38. Laterre PF, Moeremans K, Gilis P, et al. Severe sepsis: clinical trial versus daily practice. A cost analysis in Belgium [abstract no. PIN 2]. Value Health 2002 Nov-Dec; 5 (6): 561-562. Plus poster presented at the 5th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2002 Nov 3-5; Rotterdam
39. Schmid A, Schneider H, Adlof A, et al. Economic burden of illness imposed by severe sepsis in Austria. Wien Klin Wochenschr 2002 Aug 30; 114 (15-16): 697-701
40. Schmid A, Burchardi H, Clouth J, et al. Burden of illness imposed by severe sepsis in Germany. Eur J Health Econom 2002; 3: 77-82
41. Van Gestel A, Bakker J, Veraart C, et al. The costs of severe sepsis - the Netherlands, 2000 [abstract no. PIN 1]. Value Health 2002 Nov-Dec; 5 (6): 561
42. Eli Lilly and Company. Briefing document for Xigris for the treatment of severe sepsis [online]. Available from URL: www.fda.gov/ohrns/dockets/ac/01/ briefing/3787b1_01_Sponsor.pdf [Accessed 2003 Dec 8]
43. Dhainaut JF. Introduction: rationale for using drotrecogin alfa (activated) in patients with severe sepsis. Am J Surg 2002 Dec; 184 (6A Suppl.): 5S-10S
44. Morris PE, Hite RD, Ohl C. Relationship between the inflammation and coagulation pathways in patients with severe sepsis: implications for therapy with activated protein C. Biodrugs 2002; 16 (6): 403-17
45. Bradley C. Activated protein C in severe sepsis. Intensive Crit Care Nurs 2001 Jun; 17 (3): 177-8
46. Lawson WE, Ely EW. The use of drotrecogin alfa (activated) in the management of the patient with severe sepsis. Today Ther Trends 2002; 20 (2): 159-82
47. Angus DC. Drotrecogin alfa (activated): viewpoint. Drugs 2002; 62 (4): 631-2
48. Laterre PF, Levy H, Ball D, et al. The effects of drotrecogin alfa (activated) on hospital mortality, length of stay, and discharge location [letter]. Chest 2002 Oct; 122 (4 Suppl.): 51
49. Bernard GR, Macias WL, Joyce DE, et al. Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis. Crit Care 2003 Apr; 7 (2): 155-62
50. US Food and Drug Administration clinical review. Drotrecogin alfa (activated) [recombinant human activated protein C (rhAPC)] BLA #125029/0 [online]. Available from URL: http://www.fda.gov/cber/review/drotelil12101.htm [Accessed 2002 Sep 24]
51. Ely EW, Laterre PF, Angus DC, et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003 Jan; 31 (1): 12-9
52. Dhainaut JF, Laterre PF, Janes JM, et al. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 2003 Jun; 29 (6): 894-903
53. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985 Oct; 13 (10): 818-29
54. Vincent JL, Angus DC, Artigas A, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003 Mar; 31 (3): 834-40
55. Angus DC, Laterre PF, Helterbrand J, et al. The effects of drotrecogin alfa (activated) on long-term survival after severe sepsis. Chest 2002 Oct; 122 (4 Suppl.): 51
56. Ely EW, Angus DC, Williams MD, et al. Drotrecogin alfa (activated) treatment of older patients with severe sepsis. Clin Infect Dis 2003 Jul 15; 37 (2): 187-95
57. Wheeler AP, Doig C, Wright T, et al. Baseline characteristics and survival of adult severe sepsis patients treated with drotrecogin alfa (activated) in a global, single-arm, open-label trial (ENHANCE). Chest 2003; 124 (4 Suppl.): 91S
58. Vincent J-L, Light B, Wright T, et al. Global ENHANCE results indicate organ function improvement with drotrecogin alfa (activated) in severe sepsis patients. Chest 2003 Oct; 124 (4 Suppl.): 103S
59. Schein RM, Kinasewitz GT. Risk-benefit analysis for drotrecogin alfa (activated). Am J Surg 2002 Dec; 184 (6A Suppl.): S25-38
60. Laterre P, Wittebole X. Clinical review: drotrecogin alfa (activated) as adjunctive therapy for severe sepsis: practical aspects at the bedside and patient identification. Critical Care 2003; 7: 445-50
61. Angus DC, Linde-Zwirble WT, Clermont G, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003 Jan; 31 (1): 1-11
62. Manns BJ, Lee H, Doig CJ, et al. An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002 Sep 26; 347 (13): 993-1000
63. Fowler RA, Hill-Popper M, Stasinos J, et al. Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis. J Crit Care 2003 Sep; 18 (3): 181-91
64. Betancourt M, McKinnon PS, Massanari RM, et al. An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures. Pharmacoeconomics 2003; 21 (18): 1331-40
65. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1253-8
66. Quartin AA, Schein RM, Kett DH, et al. Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. JAMA 1997 Apr 2; 277 (13): 1058-63
67. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313 (7052): 275-83
68. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 1985 Summer; 5 (2): 157-77
69. Angus DC, Linde-Zwirble WT, Clermont G, et al. Cost-effectiveness of drotrecogin alfa (activated) (Xigris TM) in severe sepsis. Crit Care Med 2002 Feb; 30 (2): 493
70. Neilson A, Schneider H, Burchardi H, et al. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis: a cross-national comparison of three European countries [abstract no. PIN 5]. Value Health 2002 Nov-Dec; 5 (6): 563. Plus poster presented at the 5th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2002 Nov 3-5; Rotterdam
71. Launois R, Riou-Franca L, Guidet B, et al. Cost-effectiveness analysis of drotrecogin alfa (activated) as a treatment for severe sepsis [abstract no. 624]. Intensive Care Med 2003; 28 Suppl. 1: S161
72. Neilson AR, Burchardi H, Chinn C, et al. Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany. J Crit Care 2003; 18 (4): 217-27
73. Lucioni C, Guidi L, Mazzi S, et al. The treatment of sepsis patients with drotrecogin alfa (activated): an economic evaluation with reference to Italy. Value Health 2002 Nov; 5 (6): 562. Plus poster presented at the 5th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2002 Nov 3-5; Rotterdam
74. Sacristan JA, Prieto L, Huete T, et al. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis in Spain [abstract no. PIN 4]. Value Health 2002 Nov; 5 (6): 562. Plus poster presented at the 5th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2002 Nov 3-5; Rotterdam
75. Hjelmgren J, Ragnarson TG, Persson U, et al. Cost-effectiveness of drotrecogin alfa (activated) in treating severe sepsis in Sweden [abstract no. 353]. Intensive Care Med 2003; 29 Suppl. 1: S94
76. Neilson AR, Schneider H, Finnern HW. Comparing the cost-effectiveness of drotrecogin alfa (activated) across three European countries [abstract no. 350]. Intensive Care Med 2003; 29 (Suppl. 1): S93
77. Davies A, Hutton J, Ridley S, et al. Cost-effectiveness of drotrecogin alfa (activated) in treating severe sepsis in the UK. Intensive Care Med 2002; 28 (Suppl. 1): S161
78. Sacristan JA, Prieto L, Huete T, et al. Cost-effectiveness of drotrecogin alpha [activated] in the treatment of severe sepsis in Spain (in Spanish]. Gac Sanit 2004; 18 (1): 50-7
79. FXConverter - 164 currency converter. Results [online]. Available from URL: http://www.oanda.com/convert/classic [Accessed 2003 Nov 18]
80. Drabinski A, Williams G, Formica C. Observation evaluation of health state utilities among a cohort of sepsis patients [abstract no. PID 7]. Value Health 2001 Mar-Apr; 4 (2): 130
81. Fryback DG, Dasbach EJ, Klein R, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993 Apr-Jun; 13 (2): 89-102
82. Linden PK, Angus DC, Chelluri L, et al. The influence of clinical study design on cost-effectiveness projections for the treatment of gram-negative sepsis with human anti-endotoxin antibody. J Crit Care 1995 Dec; 10 (4): 154-64
83. Schwartz WB, Mendelson DN. Hospital cost containment in the 1980s. Hard lessons learned and prospects for the 1990s. New Engl J Med 1991 Apr 11; 324 (15): 1037-42
84. Eli Lilly and Company. Lilly launches world's largest severe sepsis clinical trial; 11,000 patients to be enrolled in study of Xigris use in patients with low risk of death [media release]. 2002 Sep 17
85. Eli Lilly and Company. Xigris. Drotrecogin alfa (activated) prescribing information. Indianapolis, 2003. 2001
86. Eli Lilly and Company. European Commission approves Eli Lilly and Company's Xigris for the treatment of severe sepsis [media release]. 2002 Aug 26
87. Wenzel RP. Treating sepsis. N Engl J Med 2002 Sep 26; 347 (13): 966-7
88. Hassan E, Mann HJ. Current issues regarding the use of drotrecogin alfa (activated). Pharmacotherapy 2002 Dec; 22 (12 Pt 2): 206S-15S
89. Sollet JP, Garber GE. Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy. Am J Surg 2002 Dec; 184 (6A Suppl.): S11-8
90. Coughlin MT, Angus DC. Economic evaluation of new therapies in critical illness. Crit Care Med 2003 Jan; 31 (1 Suppl.): S7-16
91. Chalfin DB, Teres D, Rapoport J. A price for cost-effectiveness: implications for recombinant human activated protein C (rhAPC). Crit Care Med 2003 Jan; 31 (1): 306-8
92. Lebbos J, Bradsher J, Kirkpatrick P. Drotrecogin alfa (activated). Nat Rev Drug Discov 2003 Jan; 2 (1): 13-4
93. Eli Lilly and Company. Lilly's Xigris becomes first and only medical product approved for BIPA payment in Medicare patients; approval affirms Xigris' ability to help save lives [media release]. 2002 Jul 21
94. Thompson CA. Medicare to partly cover extra cost of sepsis therapy, drug-eluting stents. Am J Health Syst Pharm 2002 Oct 1; 59 (19): 1816-7
95. Cooper LM, Linde-Zwirble W, Jacobi J. Impact of new technology payments for drotrecogin alfa (activated) the MERCURY study. Crit Care Med 2003; 31 (Suppl.): A73
96. Banks SM, Gerstenberger E, Eichacker PQ, et al. Long-term cost effectiveness of drotrecogin alfa (activated): an unanswered question. Crit Care Med 2003 Jan; 31 (1): 308-9
97. Vincent J-L, Levy MM, Macias WL, et al. Early intervention with drotrecogin alfa (activated) improves survival benefit. Crit Care Med 2003; 31 (Suppl.): A123
98. Johnston JA, Pulgar S, Ball DE, et al. The impact of timely drotrecogin alfa (activated) (Xigris) administration on hospital mortality and resource use. Crit Care Med 2003; 31 (Suppl.): A73
99. Wheeler A, Steingrub J, Linde-Zwirble W, et al. Prompt administration of drotrecogin alfa (activated) is associated with improved survival. Crit Care Med 2003; 31 (Suppl.): A120
100. Schmidt G, Bates B, Shwed McCollam J, et al. Clinical use of drotrecogin alfa (activated): patients treated in MERCURY differ from those in PROWESS. Crit Care Med 2003; 31 (Suppl.): A116
101. Steingrub J, Sanchez P, Zeckel M, et al. Safety of drotrecogin alfa (activated): results of MERCURY, a retrospective multicenter observational study. Crit Care Med 2003; 31 (Suppl.): A117
102. Cohen H, Welage LS. Strategies to optimize drotrecogin alfa (activated) use: guidelines and therapeutic controversies. Pharmacotherapy 2002 Dec; 22 (12 Pt 2): 223S-35S
103. Morris PE, Light RB, Garber GE. Identifying patients with severe sepsis who should not be treated with drotrecogin alfa (activated). Am J Surg 2002 Dec; 184 (6A Suppl.): S19-24